Sugi Predict

Sugi Predict / Compounds / Dovitinib

Dovitinib

Dovitinib

SCHEMBL248083

CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1.O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

FGFR3FLT1FLT3FLT4KDRKITPDGFRAPDGFRB

The experimentally established mechanism targets of Dovitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB known ✓ P09619 16/20 0.98
▸ KDR known ✓ P35968 16/20 0.98
▸ FLT1 known ✓ P17948 4/20 0.98
▸ FLT3 known ✓ P36888 2/20 0.98
▸ KIT known ✓ P10721 1/20 0.98
▸ PDGFRA known ✓ P16234 1/20 0.98
▸ FGFR3 known ✓ P22607 1/20 0.98
▸ FLT4 known ✓ P35916 1/20 0.98
▸ FGFR1 P11362 18/20 0.98
▸ LCK P06239 3/20 0.98
▸ MAP4K1 Q92918 2/20 0.98
▸ PLK4 O00444 1/20 0.98
▸ STK25 O00506 1/20 0.98
▸ CIT O14578 1/20 0.98
▸ RIOK3 O14730 1/20 0.98
▸ CHEK1 O14757 1/20 0.98
▸ GAK O14976 1/20 0.98
▸ CHUK O15111 1/20 0.98
▸ MUSK O15146 1/20 0.98
▸ EPHB6 O15197 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dovitinib SCHEMBL29424010 0.99 FGFR1 (1.00) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL29352967 0.99 FGFR1 (1.00) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL172687 0.99 FGFR1 (1.00) FGFR1PDGFRBKDRFLT1LCK
SCHEMBL14796707 0.96 FGFR1 (0.93) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL12003201 0.93 FGFR1 (0.85) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL29351344 0.93 FGFR1 (0.84) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL253994 0.93 FGFR1 (0.84) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL29435017 0.93 FGFR1 (0.84) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL949705 0.92 FGFR1 (0.86) FGFR1PDGFRBKDRFLT1LCK
Dovitinib SCHEMBL30567813 0.92 FGFR1 (0.86) FGFR1PDGFRBKDRFLT1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588086-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. NOVARTIS AG (CH) 2018-09-12 — — EP claimed
EP-2588086-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. Novartis AG (CH) 2013-05-08 — — EP claimed
US-20130090344-A1 Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate NOVARTIS AG (CH) 2013-04-11 — — US claimed
WO-2012001074-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. NOVARTIS AG (CH) 2012-01-05 — — WO claimed
EP-2588086-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. NOVARTIS AG (CH) 2018-09-12 — — EP disclosed
US-9545402-B2 Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate NOVARTIS AG (CH) 2017-01-17 — — US disclosed
EP-2588086-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. Novartis AG (CH) 2013-05-08 — — EP disclosed
EP-2588086-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. Novartis AG (CH) 2013-05-08 — — EP disclosed
US-20130090344-A1 Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate NOVARTIS AG (CH) 2013-04-11 — — US disclosed
WO-2012001074-A3 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE NOVARTIS AG (CH) 2012-03-22 — — WO disclosed
WO-2012001074-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. NOVARTIS AG (CH) 2012-01-05 — — WO disclosed
WO-2012001074-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. NOVARTIS AG (CH) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090344-A1 Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate LCT, LDHA, HK1 PDGFRB 3716/4885KDR 3569/4885FLT1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.